

**Title:**

**Scientific report: a case of acute pancreatitis due to liraglutide**

**Authors:**

Noe Quesada-Vázquez

DOI: 10.17235/reed.2018.5912/2018

Link: [PubMed \(Epub ahead of print\)](#)

**Please cite this article as:**

Quesada-Vázquez Noe. Scientific report: a case of acute pancreatitis due to liraglutide. Rev Esp Enferm Dig 2018.  
doi: 10.17235/reed.2018.5912/2018.



*This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.*

Accepted

CC 5912

**Scientific report: a case of acute pancreatitis due to liraglutide**

Noe Quesada-Vázquez

Digestive Disease Institute. Cleveland Clinic. Abu Dhabi

**Correspondence:** Noe Quesada-Vázquez

e-mail: noeqv@hotmail.com

**Key words:** Acute pancreatitis. Incretin-base therapies. Liraglutide. glp-1 analogues.

*Dear Editor,*

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog. GLP-1 analogues are used as a second option treatment for type 2 diabetes and weight management in obese patients (1). Data in the literature suggests an association between GLP-1 agonist use and acute pancreatitis (AP) (2). Furthermore, it has been suggested that acute pancreatitis is a potential complication of liraglutide therapy and liraglutide should be used cautiously in patients at risk of pancreatitis (3,4).

**Case report**

This case reported herein was a 44-year-old female diagnosed with acute pancreatitis based on two of three criteria when she presented to the Emergency Department with epigastric pain, which radiated to her back. Amylase and lipase levels were also significantly elevated and the abdominal ultrasound was normal. Laboratory studies were otherwise unremarkable and there was no relevant medical history. She denied alcohol use, smoking, toxic habits and herbal remedies. She had no medication allergies and no relevant family history.

Liraglutide (1.2 mg/day) was started six months before admission for weight management. Viral hepatitis and an autoimmunity screening were also negative and she did not meet any Bedside Index of Severity in Acute Pancreatitis (BISAP) score criteria. Liraglutide was discontinued indefinitely and the patient was treated conservatively with a favorable clinical course. Serum pancreatic enzymes normalized on hospital day 4 and her symptoms ceased. A re-challenge test was not performed for safety reasons.

A probable causative relationship was established between liraglutide and the acute pancreatitis in this case, using the Naranjo scale (score of 7) (5). The absence of type 2 diabetes mellitus in our patient and the absence of other risk factors for acute pancreatitis means that liraglutide is a unique causative agent of AP in this case. This case was reported to the Food and Drug Administrations' MedWatch program.

## References

1. Nauck MA, Niedereichholz U, Ettl R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. *Am J Physiol* 1997;273(5 Pt 1):E981-8. DOI: 10.1152/ajpendo.1997.273.5.E981
2. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2009;32(5):834-8. DOI: 10.2337/dc08-1755
3. Faillie J-L, Babai S, Crépin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. *Acta Diabetol* 2014;51(3):491-7.
4. Nakamura T, Ito T, Uchida M, et al. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. *Lab Investig J Tech Methods Pathol* 2014;94(1):63-78. DOI: 10.1038/labinvest.2013.133
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981;30:239-45. DOI: 10.1038/clpt.1981.154